Effects of Intraperitoneal Chemotherapy with Mitomycin C on the Prevention of Peritoneal Recurrence in Colorectal Cancer Patients with Positive Peritoneal Lavage Cytology Findings

Noura, Shingo; Ohue, Masayuki; Shingai, Tatsushi; Kano, Shingo; Ohigashi, Hajime; Yano, Masahiko; Ishikawa, Osamu; Takenaka, Akemi; Murata, Kohei; Kameyama, Masao

doi:10.1245/s10434-010-1319-2

Cited by 44 publications

(43 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Simultaneous use of CRS and HIPEC as part of the primary cancer treatment has been associated with favorable results [6][7][8][9]. It is also the focus of two active clinical trials [10,11].…”

Section: Patients To Be Included In This Clinical Pathwaymentioning

confidence: 99%

See 1 more Smart Citation

Management Of Unexpected Peritoneal Metastases With Primary Colorectal Cancer Using Second-Look Surgery With HIPEC

Sugarbaker¹,

Gléhen²

2017

Cancer Surg

View full text Add to dashboard Cite

Background: Peritoneal metastases (PM) will be unexpectedly present in approximately 10% of colorectal cancer patients having primary cancer resection. In the past this was considered to be an incurable condition with a terminal outcome. In patients determined to have peritoneal dissemination at the time of resection, the intervention was considered palliative. Recently, long term benefit from definitive treatment of PM with cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) has become a reality. These treatments are now appropriate for primary appendiceal and colorectal cancer determined to have PM at the time of resection.

show abstract

Section: Patients To Be Included In This Clinical Pathwaymentioning

confidence: 99%

“…A positive cytology may also be considered an adequate cause for secondlook HIPEC. Patients with positive cytology prior to or after primary colorectal cancer resection have an incidence of peritoneal metastases of 50% (Table 1) [9].…”

Section: Other Clinical Features That May Require a Second-look With mentioning

confidence: 99%

Management Of Unexpected Peritoneal Metastases With Primary Colorectal Cancer Using Second-Look Surgery With HIPEC

Sugarbaker¹,

Gléhen²

2017

Cancer Surg

View full text Add to dashboard Cite

show abstract

“…Various investigators have reproposed this strategy particularly in patients with free endoperitoneal cancer cells [75,76]. In 2014 Sloothaak et al [77] published a systematic review evaluating the main experiences in preventing endoperitoneal spread in advanced colorectal cancer with proactive endoperitoneal chemotherapy.…”

Section: Proactive Management Of Peritoneal Metastases From Colorectamentioning

confidence: 99%

Proactive Management for Gastric, Colorectal and Appendiceal Malignancies: Preventing Peritoneal Metastases with Hyperthermic Intraperitoneal Chemotherapy (HIPEC)

Sammartino

Biacchi

Cornali

et al. 2016

Indian J Surg Oncol

View full text Add to dashboard Cite

An integrated treatment strategy using peritonectomy procedures plus hyperthermic intraperitoneal chemotherapy (HIPEC) is now a clinical standard of care in selected patients with peritoneal metastases and primary peritoneal tumors. This comprehensive approach can offer many patients, who hitherto had no hope of cure, a good quality of life and survival despite limited morbidity. The increasingly successful results and chance of interfering in the natural history of disease has prompted research to develop for some clinical conditions a therapeutic strategy designed to prevent malignant peritoneal dissemination before it becomes clinically evident and treat it microscopically (tertiary prevention). The main factor governing successful cytoreductive surgery and predicting outcome is the extent of peritoneal spread assessed with the peritoneal cancer index (PCI). In peritoneal metastases from colorectal and gastric cancer the PCI score acquires a specific role acting as the cut-off between patients who can undergo curative surgery or palliation. Long-term results show that the only group enjoying favorable results are patients with limited disease (a statistical minority). By applying to appropriately selected patients with primary malignancies a proactive management strategy including HIPEC we can treat patients with microscopic peritoneal dissemination and therefore at PCI 0. Among treated conditions pseudomyxoma peritonei enjoys the best results. But a major future advance comes from identifying among lesions at major risk of pseudomyxoma.

show abstract

“…The comparative study was nonrandomized, and no difference in OS was observed. In another uncontrolled study, a group of CRC patients with positive cytology at the time of primary resection were selected for postoperative IP administration of mitomycin C. In a multivariate analysis, IP-CHT was the only significant prognostic factor for peritoneal recurrence survival, even though OS was not affected by the locoregional treatment [82]. These studies show that an aggressive prophylactic surgical approach associated with IP-CHT may positively modify the natural course of peritoneal disease and be of benefit in selected Table 19.…”

Section: Prophylactic Hipecmentioning

confidence: 99%

Peritoneal Carcinomatosis from Colorectal Cancer

Sommariva

Rossi²

2015

Treatment of Peritoneal Surface Malignancies

View full text Add to dashboard Cite

Effects of Intraperitoneal Chemotherapy with Mitomycin C on the Prevention of Peritoneal Recurrence in Colorectal Cancer Patients with Positive Peritoneal Lavage Cytology Findings

Cited by 44 publications

References 33 publications

Management Of Unexpected Peritoneal Metastases With Primary Colorectal Cancer Using Second-Look Surgery With HIPEC

Management Of Unexpected Peritoneal Metastases With Primary Colorectal Cancer Using Second-Look Surgery With HIPEC

Proactive Management for Gastric, Colorectal and Appendiceal Malignancies: Preventing Peritoneal Metastases with Hyperthermic Intraperitoneal Chemotherapy (HIPEC)

Peritoneal Carcinomatosis from Colorectal Cancer

Contact Info

Product

Resources

About